Scientists Reverse Alzheimer’s in Mice With 3 Doses, Cutting Amyloid 50-60% in 1 Hour
Updated
Updated · ScienceDaily · May 17
Scientists Reverse Alzheimer’s in Mice With 3 Doses, Cutting Amyloid 50-60% in 1 Hour
6 articles · Updated · ScienceDaily · May 17
Three doses of engineered nanoparticles reversed Alzheimer’s-like symptoms in mice, with brain amyloid-β levels dropping 50-60% within one hour of injection.
The particles worked as drugs themselves, repairing the blood-brain barrier and resetting LRP1 transport so the brain could resume clearing toxic waste proteins.
In a long-term test, a 12-month-old treated mouse assessed six months later behaved like a healthy animal despite an age roughly comparable to a 90-year-old human.
The study, led by IBEC and West China Hospital Sichuan University and published in Signal Transduction and Targeted Therapy, targets vascular dysfunction rather than neurons or plaques directly.
Human use remains distant: the therapy is still in animal testing, and many Alzheimer’s treatments that succeeded in mice have later failed in clinical trials.
With Alzheimer's symptoms reversed in mice, how soon could this nanotherapy be tested in humans?
Nanoparticles, exercise pills, and ultrasound all target brain health. Which new approach will win the race against Alzheimer's?
Beyond clearing plaques, can resetting the brain's own defenses be the ultimate cure for dementia?
Breakthrough Nanoparticle Treatment Achieves Full Reversal of Alzheimer’s Pathology in Mouse Models
Overview
A major breakthrough in late 2025 introduced supramolecular drugs—engineered nanoparticles designed to mimic LRP1 ligands—that can cross the blood-brain barrier and bind directly to amyloid-beta proteins. These drugs not only remove toxic species from the brain but also rejuvenate the brain’s blood vessels, restoring their natural waste-clearing function. This approach marks a shift from simply targeting plaques to repairing the brain’s own cleaning system, leading to a reversal of Alzheimer’s pathology in mice and significant improvements in cognitive function. The findings open new possibilities for future therapies and clinical trials.